Nicholas Lawrence
@nicholasjlawrence.bsky.social
Chemistry Professor at the Moffitt Cancer Center. Views personal.
ABBV-CLS-484 is a first-in-class, orally bioavailable PTPN2/N1 phosphatase inhibitor, being evaluated as a potential cancer immunotherapy agent. A rare example of a bioavailable active site phosphatase inhibitor. To be added to next year's lecture notes. Hoping for positive results in the clinic!
April 24, 2025 at 7:37 PM
ABBV-CLS-484 is a first-in-class, orally bioavailable PTPN2/N1 phosphatase inhibitor, being evaluated as a potential cancer immunotherapy agent. A rare example of a bioavailable active site phosphatase inhibitor. To be added to next year's lecture notes. Hoping for positive results in the clinic!
Great to hear the Medicinal Chemistry of phosphatase inhibitor ABBV-CLS-484 from Abbvie's Dr. Phil Kym (to the left of Dr. Jim Leahy) last week at USF Chemistry. #DrugDiscovery, #Chemistry
April 24, 2025 at 7:12 PM
Great to hear the Medicinal Chemistry of phosphatase inhibitor ABBV-CLS-484 from Abbvie's Dr. Phil Kym (to the left of Dr. Jim Leahy) last week at USF Chemistry. #DrugDiscovery, #Chemistry